ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

ACS Journal Cancer Refers I-ELCAP Studies to Office of Human Research Protections

January 6, 2012

DC Board Okay One Recompetition, Disapproves Two

November 12, 1982

New England Medical Center Discloses Case Of Two Overdoses

April 28, 1995

In Brief: NIEHS to Observe20th Anniversary Dec. 3-5 With Scientific Presentations, Big Celebration

November 21, 1986

FDA Proposes Office For Patients With Life Threatening Disease

November 13, 1992

OMB Ploy Would Delay Funding 1,500 NIH Grants From FY 1985 To 1986; Other Cuts Are Considered

January 18, 1985